Larazotide

Larazotide acetate (also known as AT-1001) is primarily being investigated as a therapeutic agent for conditions involving intestinal barrier dysfunction. Based on available clinical trial and research evidence, its main applications include:

Celiac Disease

The most established clinical application for larazotide is in celiac disease management. A completed Phase 2 safety and tolerability study (NCT00362856) evaluated larazotide acetate in celiac disease patients. However, a subsequent Phase 3 efficacy and safety trial (NCT03569007) aimed at evaluating larazotide for relief of celiac disease symptoms was terminated, suggesting challenges in demonstrating clinical efficacy at this stage of development.

Recent research indicates larazotide may help protect the intestinal mucosal barrier, which is compromised in celiac disease. The compound appears to work through various cellular mechanisms to maintain barrier function, though clinical translation of these effects remains under investigation.

Long COVID

A Phase 2 trial (NCT05747534) is currently investigating larazotide acetate (AT1001) for treating Long COVID, though this study is no longer actively recruiting participants. The rationale for this application likely relates to the compound's potential effects on barrier function and inflammation.

Post-COVID Multisystem Inflammatory Syndrome

Emerging research has explored larazotide's use in children with post-COVID multisystem inflammatory syndrome, with one study reporting effects on viral spike antigen clearance and recovery, though more evidence is needed to establish clinical efficacy.

Other Investigational Areas

Research has examined larazotide's potential in several other conditions:

• Colitis: Studies have investigated sustained-release formulations for colitis treatment
• Non-alcoholic fatty liver disease (NAFLD): Preventive effects have been observed in mouse models
• Ischemia-reperfusion injury: Research suggests protective effects against anoxia/reoxygenation injury

Current Clinical Status

The clinical development of larazotide appears mixed, with the termination of the Phase 3 celiac disease trial representing a significant setback. However, ongoing investigation in Long COVID and other barrier-related conditions suggests continued interest in the compound's therapeutic potential.

Disclaimer: This information is for educational purposes only and should not be considered personalized medical advice. Patients should consult healthcare providers regarding treatment options for their specific conditions.